Joint Action (JA) – Cancer Control

iPAAC is funded by the EU’s 3rd Health Programme fostering health in Europe by encouraging cooperation between Member States to improve health policies that benefit their citizens. The programme aims to support and complement Member States’ health initiatives.

01/04/2018 – 31/03/2021 (3 years)

Tit Albreht, National Institute of Public Health Slovenia (NIJZ)


Sciensano, Belgium

National Center of Public Health and Analyses, Bulgaria

Croatian Institute of Public Health, Croatia

Ministry of Health of the Republic of Cyprus

Institute of Health Information and Statistics of the Czech Republic

National Institute for Health and Welfare, Finland

French National Cancer Institute

Federal Ministry of Health, Germany

7th Health Region of Crete

National Institute of Oncology, Hungary

Department of Health, Ireland

National Institute of Health, Italy

Ministry of Health of the Republic of Lithuania

Ministry for Health – Government of Malta

Institute of Oncology of the Republic of Moldova

National Institute for Public Health and the Environment, Netherlands

Oslo University Hospital

National Institute of Public Health – National Institute of Hygiene, Poland

Ministry of Health of Portugal

National Institute of Public Health, Romania

Institute of Public Health of Serbia

Biomedical Research Center of the Slovak Academy of Sciences

Catalan Institute of Oncology

Institute of Oncology Ljubljana

Masaryk University

Cancer Society of Finland

German Cancer Research Center

German Cancer Society

Technical University Dresden

University of Cologne

Italian Ministry of Health

Vilnius University Hospital Santaros Klinikos

‘Marius Nasta’ Pneumophtisiology Institute

Oncology Institute ‘Prof. Dr. Ion Chiricuţă’

Emergency Clinical County Hospital Craiova

Clinical Centre of Kragujevac

Faculty of Medicine, University of Belgrade

Institute for Oncology and Radiology of Serbia

Public Health Institute Niš

Institute of Public Health of Vojvodina

Oncology Institute of Vojvodina Provincial Secretariat for Health Care

Foundation for the Promotion of Health and Biomedical Research of Valencia Region

Why it matters

Cancer continues to present one of the key public health challenges in the European Union. Targeting both EU-level policy-makers and decision-makers at national, regional and local level, iPAAC focuses on implementation of the outcomes of the European Partnership for Action Against Cancer (EPAAC) and Cancer Control (CanCon), and constantly expands its activities to new cancer control issues such as genomics, innovative therapies and the use of registries.

This Joint Action also hopes to provide better efficacy for dealing with neglected cancers, through the development of new key indicators to assess clinical patient pathways and healthcare-related costs of cancer and its intervention, particularly in the case of pancreatic cancer. At the European Union level, iPAAC adds value by enhancing collaboration in the field of cancer with extensive exchange of good practices, successful implementation of different programmes and gradual reduction of the cancer burden. At Member State level, iPAAC employs its Roadmap on Implementation and Sustainability of Cancer Control Actions to support national, regional and local decision-makers in implementing innovation.

What ECPC does

ECPC integrates the patient’s voice within iPAAC by contributing to guidelines for cancer information and registries, advising on the selection of epidemiological indicators on cancer prevalence and survivorship, participating in a consensus meeting to define neglected cancers using the case of pancreatic cancer, and supporting a paradigm shift on the use of genomics. ECPC also contributes to the successful dissemination of the project’s deliverables and is collaborating to organise an expert workshop and 2 conference meetings actively supporting networking and mapping of contacts.

EU flag logo

This project is funded by the European Union

“ECPC calls for embracing innovation in cancer research, treatments and care, and specifically for recommended measures to improve the rates of approval of novel therapies and the supply of these to patients, and to reinforce the negotiation capacities of Member States. The iPAAC Roadmap is a powerful tool for achieving these very goals.”

ECPC’s Manifesto for the 2019 European Elections